Member Info for MisterPositive

GDR touched £3 back in 2020 if i am correct.

Are the headlines we all want to see.

Made in U.K

BTW - I was referring to 80p as only short term quick flurry between Feb and March.

I see long term GDR price in £££ unless one of the BIG PHARMA throw in their towel bit early to buy it on the cheap before GDR could mature and grow to a mid tier Bio-tech.

Nissangtr
70p is way too low for a Take over.

GSK bought Human Genome Sciences Inc for around $14.25 per share back in 2012.

Let GDR grow and mature with time bringing both AIHL and Stroke tests to market. AIHL being unique to GDR with NO comparable test in the market should put GDR on world stage with news / media coverage in both UK and USA.

Will not rule out Global distribution deal with Beckman Coulter which as we know is owned by NYSE listed giant Danaher Corp.

We all want to see GDR flourish as "Made in UK" brand on the World stage. Our time is near. GLA

I do not have time at all to fufff around for few points here and there. Will wait for 80p ;-)

Flash headline from NICE tomorrow after 21 Feb consultation end date and this should be 45p plus

AIHL is unique to GDR, no other test on the market. GDR is "first to market" which is very significant.

Dont have to wait for full report in March.

Also noticed some funny posts about FDA yesterday....dont have the time and energy to waste on that. FDA update due anyday. Happy to wait on that one.

NICE consultation on Stroke to start on 21 April.

Already received preliminary recommendation from NICE on 9 Feb when this opened around 38p

Expect some sort of FLASH headlines from NICE tomorrow or Wednesday.

FDA update from US also due any day now.

Thanks Nissangtr.
Both AIHL and Stroke tests are with NICE.

Looking at their published Schedule, Stroke test goes into NICE consultation in April straight after AIHL tests full report publication in March.

Excellent setting here for continued strong momentum at GDR with news rich period in both UK and USA and the resultant media / news / social media coverage that should follow on.

We could see 80p - 100p lot sooner IMO.

NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme

From 22 Aug 2022 RNS.

"The Genedrive® CYP2C19 test is a simple, rapid point of care test, with no requirement for result interpretation and provides results in a clinically actionable timeframe. The genedrive test has been designed to have extended coverage across ethnic populations, which is important because the frequency of the various CYP2C19 related genetic changes differs across ethnicities."

Exoected completion date Q1 2023.

GDR potentially have Global reach here. If GDR can capture only 2% of the $65.45 billion Stroke diagnostics market, that would be $1.3 billion in top line revenue.

Let the numbers sink in...gives an idea where we headed. only 92.5m total shares in issue.

Last Thursday opened around 40% higher on just preliminary NICE recommendations.

Simply do not want to be out of this any day.

GSK bought Human Genome Sciences Inc for $14.25 per share cash offer back in 2012. Different products but gives you an idea of where this can go if GDR play their cards right with both AIHL and Stroke tests.

Gene therapy and diagnostics is the future and GDR got not one but two cutting edge products.

GLA.

We should get FLASH headline news like we did on 9 Feb on day 1 of their consultation period.

It opened around 36p or 38p last Thursday. Could see similar or higher open depending on where we close on Monday.

Genedrive is really well positioned to take huge market share in Stroke test market with their cutting edge stroke marker test with results delivered within an hour.

Orhers take many weeks which is far too long. You need early detection with these. Stroke marker tests also with NICE and should be next after AIHL

GDR will very soon be on BIG PHARMA radar.

We should be getting FDA update any day now.

NICE preliminary recommendation for AIHL tests already given on first day of the consultation period which ends next Tue (21 Feb).

Stroke marker test would be next up. Also with NICE.

If FDA update also comes next week then this can really Zoom higher in a flash to 60p - 80p bracket or higher with only 92.5m total shares in issue.

Earl is right. Very clear in the RNS. Only helping with technical studies for extraction methods.

CLON has never owned any Lithium licence in Bolivia.

Good for some to make some money but some folks putting wrong spin on things for their own profits. Made some decent money here but swtched to GDR now. Good luck to all.

SystemZero
Blimey !!! You either need a NEW SYSTEM or upgrade your Software....LoL

Amateur traders get spooked easily. Experience ones know the MMs games and can see right through them.

Only 2 ways MMs can grab your shares when looking to fill big orders. Raise it first then a little tree shake hoping some nuts will fall off and they always do...LoL

Plan B is raise the bid to attract few sellers.

By the looks.

Defo some STEALTH buying going on in the background looking at the trading pattern today.

Agree. This got to 39.60p last Thursday on preliminary NICE approval on Day 1 of their consultation start date.

NICE consultation period ends on 21 Feb (Tue).
One news flash next Tue from NICE and this could simply run away.

Add to the mix FDA update could land any day. If that lands on Monday and news flash from NICE on Tuesday, then yes this could run away towards 80p + plus might even flirt with £1.00

Some of the sellers would be scrambling to get back in a hurry. Dont be the one caught with your pants down....LoL.

Buys / sells not reported correctly in my opinion.